Recent Updates
Recently added Catalysts

SGN-CD70A

Phase 1

Renal Cell Carcinoma | Small molecule | Oncology |Pfizer, Inc.|Last Updated: Apr 19, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment38
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02216890Safety Study of SGN-CD70A in Cancer PatientsPHASE1 COMPLETED 38 — — Aug 1, 2014Feb 15, 2017Apr 19, 201817 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of adverse events
Through 1 month following last dose
Incidence of laboratory abnormalities
Through 1 month following last dose
Secondary Endpoints
Blood concentrations of SGN-CD70A and metabolites
Through 3 to 6 weeks after dosing
Incidence of antitherapeutic antibodies
Through 1 month following last dose
Objective response rate
Through 1 month following last dose
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
SGN-CD70AEXPERIMENTAL -
Interventions
NameTypeDescription
SGN-CD70ADRUGGiven intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites17

Inclusion Criteria: * Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma * Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies * Confirmed positive CD70 expression on tumor tissue * Ea...

Countries:United States
Unlock Eligibility Criteria